Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help...

Full description

Bibliographic Details
Main Authors: Pengfei Jin, Jingxin Li, Hongxing Pan, Yanfei Wu, Fengcai Zhu
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00481-y

Similar Items

Similar Items